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Background: This study aimed to determine if associations of pre-diagnostic percent breast density, absolute dense area, and
non-dense area with subsequent breast cancer risk differ by the tumour’s molecular marker status.
Methods: We included 1010 postmenopausal women with breast cancer and 2077 matched controls from the Nurses’ Health
Study (NHS) and the Nurses’ Health Study II (NHS II) cohorts. Breast density was estimated from digitised film mammograms using
computer-assisted thresholding techniques. Information on breast cancer risk factors was obtained prospectively from biennial
questionnaires. Polychotomous logistic regression was used to assess associations of breast density measures with tumour
subtypes by the status of selected tissue markers. All tests of statistical significance were two sided.
Results: The association of percent density with breast cancer risk appeared to be stronger in ER as compared with ERþ
tumours, but the difference did not reach statistical significance (density X50% vs o10% odds ratio (OR)¼ 3.06, 95% confidence
interval (CI) 2.17–4.32 for ERþ ; OR¼ 4.61, 95% CI 2.36–9.03 for ER , Pheterogeneity¼ 0.08). Stronger positive associations were
found for absolute dense area and CK5/6 and EGFR as compared with respective marker-positive tumours
(Pheterogeneity¼ 0.002 and 0.001, respectively). Stronger inverse associations of non-dense area with breast cancer risk were found
for ER as compared with ERþ tumours (Pheterogeneity¼ 0.0001) and for ARþ , CK5/6þ , and EGFRþ as compared with
respective marker-negative tumours (Pheterogeneity¼ 0.03, 0.005, and 0.009, respectively). The associations of density measures with
breast cancer did not differ by progesterone receptor and human epidermal growth factor receptor 2 status.
Conclusions: Breast density influences the risk of breast cancer subtypes by potentially different mechanisms.
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Mammographic breast density is a well-established and strong
predictor of breast cancer risk (McCormack and dos Santos Silva,
2006). Appearance of the breast on the mammogram is a reflection
of the amount of fat, connective tissue, and epithelial tissue in the
breast (Tamimi et al, 2007). Women with 75% or greater percent
breast density (proportion of the total breast area that appears
dense on the mammogram) are at four- to six-fold greater risk of
breast cancer compared with women with predominantly fatty
breasts (Boyd et al, 1995, Byrne et al, 1995, Tamimi et al, 2007).
Absolute dense area of the breast that represents fibroglandular
tissue has been shown to be positively associated with breast cancer
risk while findings for the association between non-dense area of
the breast (representing adipose tissue) and breast cancer risk have
been conflicting (Pettersson et al, 2014).
Breast cancer is a heterogeneous disease; different molecular
subtypes of breast cancer have distinct clinico-morphological
features and biomarker expression that influence patient survival
(Arpino et al, 2004, Putti et al, 2005, Phipps et al, 2010). We have
recently reported a stronger association of percent breast
density with the risk of more unfavourable oestrogen receptor-
negative breast tumours (ER ) as compared with oestrogen
receptor-positive tumours (ERþ ) among postmenopausal women
(Yaghjyan et al, 2011). Also, a large pooled analysis showed a
stronger association of percent density with ER tumours among
younger women suggesting that high density may play an
important role in tumour aggressiveness (Bertrand et al, 2013).
Whether the associations of breast density with breast cancer risk
differ by status of other tissue markers implicated in breast cancer
aetiology and prognosis is unknown. Understanding these
differences might help to identify biological pathways linking high
density to specific breast cancer subtypes. We analysed prospective
data in postmenopausal women from the Nurses’ Health Study
(NHS) and the Nurses’ Health Study II (NHS II) cohorts to
determine if there are differences in the associations of percent
breast density, absolute dense area, and non-dense area with
subsequent risk of breast cancer according to the tumour’s status of
the following tissue markers involved in cellular proliferation,
differentiation, and angiogenesis that have been shown to influence
tumour aggressiveness: oestrogen receptor (ER), progesterone
receptor (PR), human epidermal growth factor receptor 2
(HER2), proliferation marker Ki67, androgen receptor (AR),
cytokeratins 5/6 (CK5/6), epidermal growth factor receptor
(EGFR), and vascular endothelial growth factor (VEGF).
MATERIALS AND METHODS
Study population and design. Women included in this study
were selected from participants of the NHS and NHS II cohorts.
These prospective cohorts followed registered nurses in the United
States who were 30–55 years (NHS) or 25–42 years old (NHS II) at
enrolment. After administration of the initial questionnaire, the
information on breast health risk factors and any cancer diagnoses
was updated biennially. More detailed description of the cohort has
been published elsewhere (Colditz and Hankinson, 2005).
We used a nested case-control study design to examine the
association between three breast density measures with breast
tumour subtypes defined based on the selected marker’s status.
Details of this nested case-control study have been previously
described (Yaghjyan et al, 2011). Briefly, using incidence density
sampling, women who did not have any type of cancer at the time
of the cases’ breast cancer diagnosis (controls) were matched with
women diagnosed with in situ or invasive breast cancer (cases)
during the follow-up period from 1 June 1989 through 30 June
2004 for NHS and from 1 June 1996 to 30 June 2007 for NHS II
(Colditz and Hankinson, 2005). Breast cancer cases were
confirmed through medical record review by trained personnel.
Because the original study was designed to evaluate associations
between circulating biomarkers and breast cancer risk, the cases
were matched with controls on age, menopausal status, post-
menopausal hormone use (current vs not current) at blood
collection, and day and time of blood collection. This study was
approved by the Committee on the Use of Human Subjects in
Research at Brigham and Women’s Hospital. All participants
provided written informed consent.
We attempted to obtain mammograms closest to the time of
blood collection from 2368 eligible cases and 4450 controls. Of the
5189 women with available mammograms, 3234 cases and controls
combined (62%) were postmenopausal at the time of both the
mammogram and the reference date (date of diagnosis for cases
and their matched controls). Owing to the limited number of
premenopausal women with available marker data we were unable
to evaluate the associations of density with breast cancer subtypes
in premenopausal women. We further restricted our analysis to
postmenopausal cases with information on at least one of the tissue
markers. The final study population included 1010 cases and 2077
controls (Figure 1).
Mammographic breast density. The screening mammogram
before the reference date was used for density measurements.
The average time between the mammogram date and the date of
breast cancer diagnosis was 4.8 years (interquartile range
(IQR)¼ 2–7 years) for NHS I and 3.0 years (IQR¼ 1–5 years)
for NHS II. The average time between mammogram and the
reference date of controls was 4.2 years (IQR¼ 1–7 years) for NHS
I and 1.5 years (IQR¼ 0–5 years) for NHS II. All mammograms in
the study were film (analogue) mammograms. To quantify
mammographic density, the craniocaudal views of both breasts
were digitised at 261 mm per pixel with a Lumisys 85 laser film
scanner (Lumisys, Sunnyvale, CA, USA). The Cumulus software
(University of Toronto, Toronto, Canada) was used for computer-
assisted determination of the absolute dense area, non-dense area,
and percent density (Byng et al, 1996). During this assessment, the
observer was blinded to the participant’s case-control status. As
reported previously, the measure of mammographic breast density
from NHS I mammograms was highly reproducible (within-person
intraclass correlation coefficient was 0.93) (Tamimi et al, 2007). All
NHS II images were read by a single reader in two batches of
mammograms B3 years apart. Cases and their matched controls
were included in the same batch. Although within batch
reproducibility was high (interclass correlation coefficient 0.90
and greater) (Pettersson et al, 2011), density measures varied
across the two NHS II batches. We included a small subset of
identical mammograms in both batches to account for batch drift
in density measurement readings. The density measures from the
second batch of NHS II mammograms were adjusted to account
for the effect of batch on density measurements, as previously
described (Bertrand et al, 2012).
Because breast densities of the right and left breast for an
individual woman are strongly correlated (correlation
coefficient¼ 0.92–0.96 for density estimated from right vs left
craniocaudal views) (Byng et al, 1996), the average density of both
breasts was used in this analysis.
Breast cancer tissue markers. Information on the tumour’s ER,
PR, and HER2 status was obtained primarily from pathology
reports and medical records. For breast cancers with missing
receptor data from pathology reports, the receptor status was
obtained from immunohistochemical staining performed on
paraffin sections of the tumour tissue microarray (TMA) according
to a standard protocol (Tamimi et al, 2008). Of all cases in the
study, information on ER, PR, and HER2 status was available for
94% (n¼ 933), 93% (n¼ 916), and 71% (n¼ 701), respectively.
Among women with receptor status information, ER, PR, and
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HER2 receptor status was available from the pathology reports for
94%, 93%, and 44% of the tumours, respectively. Information on
Ki67, AR, CK5/6, EGFR, and VEGF status was obtained from
TMA only and was available for 16% (n¼ 160), 41% (n¼ 406),
29% (n¼ 285), 30% (n¼ 297), and 18% (n¼ 182) of cases,
respectively.
Variation in the number of cases with available marker data is
explained by the source of marker data (pathology reports and
TMA (ER, PR, HER2) vs TMA only (all other markers)) as well as
funding support for quantification for each of the markers.
Currently, tissue blocks have been obtained and TMAs created for
B0% of all eligible cases in the cohort. However, as quantification
of each of the markers is supported by a different grant, not every
TMA are stained and scored at the same time for all of these
markers resulting in variation in the number of cases with available
marker data across the markers.
Immunostained TMA sections were reviewed by an expert
pathologist and visually scored for the percentage of cells that
stained positively for each of the markers. For ER and PR,
positivity from TMA was defined as 41% of tumour cell nuclei
staining (Hefti et al, 2013). For AR, positivity from TMA was
defined as 410% of tumour cell nuclei staining. (Tamimi et al,
2008) Moderate (2þ ) or strong (3þ ) membrane staining (as
opposed to low (1þ ) or none (0)) for HER2 in more than 10% of
the tumour cells was used as the cut-off for tumour’s
HER2 positivity (Tamimi et al, 2008). Cases were considered
CK5/6-positive or EGFR-positive if any staining was detected in
the tumour cells, including only focal (Collins et al, 2011). VEGF-
positivity was defined as any staining in the cytoplasm of tumour
cells (Liu et al, 2011).
We quantified Ki67 expression with the aid of computational
image analysis, implemented with Definiens Tissue Studio
(Munich, Germany). For each core, we computed the number of
total nuclei and the number of Ki67-positive nuclei. We aggregated
counts of Ki67-positive nuclei and total nuclei across a patient’s
TMA cores, and cases were considered Ki67-positive if the sum of
the percentage of Ki67-positive nuclei across cores was 14% or
greater (Cheang et al, 2009).
Covariates. Information on breast cancer risk factors was
obtained from the biennial questionnaires before the reference
date. Women were considered to be postmenopausal if they
reported: (1) no menstrual periods within the 12 months before
blood collection with natural menopause, (2) bilateral oophor-
ectomy, or (3) hysterectomy with one or both ovaries retained and
were 54 years or older for ever smokers or 56 years or older for
never smokers (Willett et al, 1983).
Statistical analysis. We used Wilcoxon–Mann–Whitney test to
analyse the difference in breast density distributions in cases and
controls. We used unconditional logistic regression to analyse the
association between breast density measures and breast cancer risk,
while adjusting for the following potential confounders in the fully
adjusted logistic regression models: age at diagnosis (continuous,
years), body mass index (continuous, kgm 2), age at menarche
(o12, 12, 13,413 years), parity and age at first birth (nulliparous,
1–4 children/o25 years, 1–4 children/25–29 years, 1–4 children/
X30 years, X5 children/o25 years, X5 children/X25 years),
postmenopausal hormone use (never, ever, unknown), age at
menopause (o46, 46–o50, 50–o55,X55 years, unknown), family
history of breast cancer (yes, no), alcohol consumption
(0,o5, 5 too15,X15 g per day), and study cohort (NHS, NHS II).
Percent breast density was categorised as o10% (referent),
10–24%, 25–49%, andX50%. Absolute dense and non-dense areas
were categorised as quartiles based on their distribution in
controls (absolute dense area: o19 cm2 (referent), 19–o35 cm2,
35–o61 cm2, X61 cm2; non-dense area: o83 cm2 (referent),
83–o138 cm2, 138–o208 cm2, X208 cm2).
Differences in the association of breast density with receptor-
specific tumour subtypes were investigated using polychotomous
logistic regression (Tamimi et al, 2007). In this analysis, the
outcome has three levels that include controls and two breast
cancer subtypes defined based on the receptor status (receptor-
Cases
n = 2368
1612 NHS I & 756 NHS II
n = 2,149
1504 NHS I & 645 NHS II
n = 1750
446 NHS I & 1077 NHS II
n = 1155 cases
1042 NHS I & 113 NHS II
n = 1010
909 NHS I & 101 NHS II
n = 3788
2512 NHS I & 1276 NHS II
n = 3439
2362 NHS I & 1304 NHS II
n = 2077 cases
1794 NHS I & 283 NHS II
n = 2077 cases
1794 NHS I & 283 NHS II
Controls
n = 4450
2857 NHS I & 1593 NHS II
Eligible
Consented
Usable
mammograms
Postmenopausal at
mammogram and
reference date
Have information
on at least one
tissue marker
Abbreviations: NHSI – Nurses’ Health Study; NHSII – Nurses Health Study ll
Figure 1. Diagram of participant selection.
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positive and receptor-negative, for e.g., ERþ and ER breast
cancer). In additional analysis, we also compared these associations
in ERþ /PRþ and ER /PR tumours. We did not analyse the
association between breast density and breast cancer risk by
combined ER, PR, and HER2 (ER/PR/HER2) status or by
combined CK5/6/EGFR status because the small number of
tumours in some subsets did not provide sufficient power to draw
meaningful conclusions. For example, defining subtypes based on
ER, PR, and HER2 resulted in the following numbers: ERþ /PRþ /
HER2 n¼ 356; ERþ /PRþ /HER2þ n¼ 82; ER /PR /
HER2þ n¼ 39, ER /PR /HER2 n¼ 57. The numbers
further became much smaller when CK5/6, EGFR and Ki67 were
considered. We used a likelihood ratio test to compare a model
with separate mammographic density slopes in each case group
with a model with a common slope. This method has been
described in detail elsewhere (Yaghjyan et al, 2011). In this
analysis, the density measures were modelled using respective
medians within each of the density categories. For all analyses, the
level of statistical significance was assessed at a¼ 0.05. All tests
were two sided.
Because the ER and PR status were moderately correlated, in a
secondary analysis we used previously published method to
examine associations of percent density with breast cancer by ER
status while adjusting for PR (Rosner et al, 2013). All analyses
except the test of heterogeneity were performed using SAS software
(version 9.2, SAS Institute, Cary, NC, USA). The test of
heterogeneity from polychotomous logistic regression models was
done using STATA version 11.0 (Stata Corp, College Station, TX,
USA).
RESULTS
In this nested case-control study of 1010 postmenopausal women
diagnosed with breast cancer and 2077 matched controls, cases had
a higher median percent breast density (28.1% vs 21.6%,
Po0.0001), higher median absolute dense area (45.1 vs 35.4 cm2,
Po0.0001) and smaller median area of non-dense breast tissue
(120.5 vs138.5 cm2, Po0.0001) as compared with controls.
Distribution of breast cancer risk factors in this study population
is presented in Table 1. Cases were more likely to have a history of
postmenopausal hormone use (76.1% vs 71.6%; P¼ 0.01), a family
history of breast cancer (19.6% vs 14.4%; Po0.001), a confirmed
benign breast disease (33.4% vs 25.8%; Po0.0001), and older age at
natural menopause (48.9 vs 48.4; P¼ 0.02) as compared with
controls. Cases and controls did not differ significantly with respect
to other risk factors.
In the multivariable analysis, higher percent density was
associated with breast cancer risk increase (X50% vs o10%, odds
ratio (OR)¼ 3.18, 95% confidence interval (CI) 2.32–4.35, Ptrend
o0.0001). Larger absolute dense area was associated with an
increase in breast cancer risk (4th vs 1st quartile, OR¼ 1.93, 95%
CI 1.52–2.45, Ptrend o0.0001), while larger non-dense area was
associated with breast cancer risk decrease (4th vs 1st quartile,
OR¼ 0.52, 95% CI 0.40–0.68, Ptrend o0.0001) (Supplementary
table 1).
Breast density and breast cancer risk according to the marker
status. Correlations of tissue markers with each other are
presented in Table 2. We observed a positive moderate correlation
of ER with PR (correlation coefficient r¼ 0.54, Po0.0001) and AR
(r¼ 0.41, Po0.0001) and negative moderate correlation with
EGFR (r¼  0.44, Po0.0001). CK5/6 was moderately correlated
with EGFR (r¼ 0.58, Po0.0001). None of the other markers were
correlated with each other.
Percent breast density. Percent density was positively associated
with all marker-defined subtypes of breast cancer (Table 3). The
association of percent density with breast cancer risk appeared to
be stronger in ER tumours as compared with ERþ tumours, as
we reported previously.(Yaghjyan et al, 2011) This difference in
associations by ER status, however, did not reach statistical
significance (density X50 vs o10% OR¼ 3.06, 95% CI 2.17–4.32
for ERþ tumours; OR¼ 4.61, 95% CI 2.36–9.03 for
Table 1. Characteristics of postmenopausal women in the study, by disease status
Characteristic
Cases
(N¼1010) Controls (N¼2077) P-for difference between cases and controls
a
Median % mammographic breast density 28.1 21.6 o0.001
Median absolute dense area, cm2 45.1 35.4 o0.001
Median non-dense area, cm2 120.5 138.5 o0.001
Mean (s.d.)
Age at mammogram, years 59.2 (7.3) 59.2 (7.5) 0.88
Age at menarche, years 12.5 (1.6) 12.5 (1.4) 0.42
Age at natural menopause, years 48.9 (5.1) 48.4 (5.6) 0.02
Body mass index at diagnosis, kgm 2 26.4 (4.9) 26.5 (5.3) 0.57
Alcohol use at diagnosis, g per day 5.5 (9.2) 5.2 (8.8) 0.30
Frequency (%)
Parity and age at first child’s birthb 0.38
Nulliparous 92 (9.1) 156 (7.5)
1–4 children with age at first birth o25 years 346 (34.3) 771 (37.1)
1–4 children with age at first birth of 25–29 years 308 (30.5) 620 (30.0)
1–4 children with age at first birth of X30 years 100 (9.9) 199 (9.6)
X5 children with age at first birth of o25 years 88 (8.7) 207 (10.0)
X5 children with age at first birth of X25 years 60 (5.9) 112 (5.4)
Postmenopausal hormone therapy 0.01
Never used hormones 213 (21.1) 538 (25.9)
Ever used hormones 769 (76.1) 1486 (71.6)
With unknown hormone use status 28 (2.8) 53 (2.6)
Family history of breast cancer 198 (19.6) 298 (14.4) o0.001
Benign breast disease 337 (33.4) 535 (25.8) o0.001
aP-values for Wilcoxon–Mann–Whitney test (density), two-sample t-test (continuous variables), or w2-test (categorical variables).
bTwenty-eight women (12 controls and 16 cases) have missing values.
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Table 2. Correlations between eight tissue markers evaluated among 1010 cases included in the study
Spearman correlation coefficient (P-value), n
PR (n¼916) HER2 (n¼701) AR (n¼406) CK5/6 (n¼285) EGFR (n¼297) VEGF (n¼182) Ki67 (n¼160)
ER (n¼933) 0.54 (o0.0001)
915
0.19 (o0.0001)
671
0.41 (o0.0001)
382
 0.10 (0.08)
285
 0.44 (o0.0001)
299
0.09 (0.27)
160
0.31 (0.0001)
150
PR – 0.16 (o0.0001)
657
0.27 (o0.0001)
371
 0.12 (0.03)
288
 0.24 (o0.0001)
301
0.03 (0.73)
147
0.21 (0.01)
145
HER2 – – 0.08 (0.10)
405
 0.06 (0.31)
282
0.14 (0.02)
295
0.01 (0.89)
178
0.02 (0.83)
159
AR – – – 0.08 (0.27)
202
0.13 (0.06)
202
0.19 (0.01)
177
0.29 (0.0007)
134
CK5/6 – – – – 0.58 (o0.0001)
274
NEa 0.13 (0.24)
78
EGFR – – – – – NEb 0.13 (0.25)
79
VEGF – – – – – – 0.21 (0.07)
76
Abbreviations: AR¼ androgen receptor; CK5/6¼ cytokeratins 5/6; EGFR¼ epidermal growth factor receptor; ER¼oestrogen receptor; HER2¼human epidermal growth factor receptor 2;
Ki67¼proliferation marker; PR¼progesterone receptor; VEGF¼ vascular endothelial growth factor.
aNon estimable: all tumours CK5/6.
bNon estimable: all tumours EGFR– and VEGF.
Table 3. Association of percent breast density with the risk of marker-defined subtypes of breast cancer in postmenopausal
womena
Tumor subtype by receptor status
Marker-positive Marker-negative
Tumour Marker Percent density category No. cases/controls OR (95% CI) No. cases/controls OR (95% CI) P-valueb
ER Total 768/2052 165/2052
o10% 112/461 1.00 (referent) 17/461 1.00 (referent) 0.08
10–24% 224/727 1.36 (1.04–1.77) 48/727 1.78 (1.00–3.17)
25–49% 312/651 2.39 (1.82–3.14) 65/651 2.75 (1.53–4.95)
X50 120/213 3.06 (2.17–4.32) 35/213 4.61 (2.36–9.03)
Ptrend o0.0001 o0.0001
PR Total 633/2052 283/2052
o10% 94/461 1.00 (referent) 32/461 1.00 (referent) 0.63
10–24% 176/727 1.27 (0.95–1.69) 96/727 1.91 (1.25–2.94)
25–49% 261/651 2.37 (1.77–3.18) 102/651 2.37 (1.52–3.72)
X50 102/213 3.04 (2.10–4.40) 53/213 3.95 (2.34–6.65)
Ptrend o0.0001 o0.0001
HER2 Total 164/2052 537/2052
o10% 21/461 1.00 (referent) 76/461 1.00 (referent) 0.43
10–24% 51/727 1.56 (0.91–2.68) 161/727 1.38 (1.01–1.87)
25–49% 74/651 2.89 (1.68–4.98) 210/651 2.16 (1.57–2.96)
X50 18/213 2.39 (1.16–4.89) 90/213 2.99 (2.02–4.42)
Ptrend 0.001 o0.0001
Ki67 Total 42/2052 118/2052
o10% 5/461 1.00 (referent) 14/461 1.00 (referent) 0.47
10–24% 10/727 1.43 (0.47–4.39) 32/727 1.69 (0.88–3.26)
25–49% 18/651 3.48 (1.17–10.39) 55/651 3.74 (1.95–7.20)
X50 9/213 6.74 (1.90–23.83) 17/213 3.96 (1.76–8.93)
Ptrend 0.0003 o0.0001
CK5/6 Total 50/2052 235/2052
o10% 9/461 1.00 (referent) 30/461 1.00 (referent) 0.46
10–24% 13/727 1.05 (0.44–2.55) 74/727 1.58 (1.00–2.49)
25–49% 23/651 2.43 (1.03–5.78) 94/651 2.47 (1.55–3.93)
X50 5/213 2.26 (0.67–7.62) 37/213 3.29 (1.85–5.84)
Ptrend 0.03 o0.0001
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ER tumours, Pheterogeneity¼ 0.08). In the analysis of associations
by ER status adjusted for PR status (915 cases), the difference in the
association by ER status did not reach statistical significance
(Pheterogeneity¼ 0.20). In the additional analysis comparing ERþ /
PRþ and ER /PR tumours, the association of percent density
appeared to be stronger in ER /PR tumours (OR¼ 4.59, 95%
CI 2.15–9.83 vs OR¼ 3.03, 95% CI 2.07–4.43); the difference,
however, did not reach statistical significance (Pheterogeneity¼ 0.35).
No differences across the subtypes were observed for any of the
other markers (Table 3).
Absolute dense area. In the analyses by the tumour’s ER, PR, and
HER2 status, absolute dense area was positively associated with
increased breast cancer risk in both marker-positive and marker-
negative tumours and these subset-specific associations were
similar (Table 4). The association of absolute dense area was
similar while comparing ERþ /PRþ and ER /PR tumours
(Pheterogeneity¼ 0.32).
In the analysis by AR, CK5/6, and EGFR, the differences in
subset-specific associations were significant for CK5/6
(Pheterogeneity¼ 0.002) and EGFR (Pheterogeneity¼ 0.001) and were
marginally significant for AR (Pheterogeneity¼ 0.07).
Associations of absolute dense area with Ki67þ and Ki67
tumours were similar. Absolute dense area was not associated with
the risk of breast cancer subtypes defined by VEGF status.
Non-dense area. In the analyses by tumour ER and PR status, non-
dense breast area was inversely associated with breast cancer risk in
both marker-positive and marker-negative tumours (Table 4). The
magnitude of the association was stronger in ER (4th vs 1st
quartile OR¼ 0.26, 95% CI 0.14–0.46) as compared with ERþ
tumours (OR¼ 0.60, 95% CI 0.45–0.80; Pheterogeneityo0.0001). In the
additional analysis comparing ERþ /PRþ and ER /PR
tumours, the association of percent density was stronger in ER /
PR tumours (4th quartile vs 1st quartile: OR¼ 0.30, 95% CI 0.16–
0.56 vs OR¼ 0.56, 95% CI 0.41–0.77, Pheterogeneity¼ 0.0073).
The difference in the associations of non-dense area with breast
cancer in Ki67þ and Ki67 tumours did not reach statistical
significance, but the risk estimates suggested a possible stronger
inverse association in Ki67 tumours (4th vs 1st quartile
OR¼ 0.44 for Ki67þ and OR¼ 0.26 for Ki67 tumours). The
association between non-dense area and breast cancer risk was
stronger in ARþ (4th vs 1st quartile OR¼ 0.27, 95% CI 0.17–0.43)
as compared with AR tumours (OR¼ 0.62, 95% CI 0.33–1.19,
Pheterogeneity¼ 0.03). We found significant differences in the
association of non-dense area with breast cancer by status of
CK5/6 and EGFR (Pheterogeneity¼ 0.005 and 0.009, respectively)
(Table 4). In the analyses by tumour’s PR, HER2, and VEGF status,
the inverse associations of non-dense breast area with breast cancer
risk were similar.
In an additional analysis, we mutually adjusted the risk
estimates for absolute dense and non-dense areas by including
both of the density measures in the model simultaneously. The risk
estimates for both absolute dense area and non-dense area
remained essentially unchanged suggesting independent nature of
the observed associations (data not shown). We found no
correlation between absolute dense are and non-dense area
(correlation coefficient¼ 0.02).
In secondary analyses, we excluded women diagnosed
with breast cancer within 2 years of their mammogram from the
current analysis; the results were not affected. We also used
ASCO/CAP clinical definition of HER2 positivity (as 3þ
membrane staining as opposed to 2þ , 1þ or none) in additional
analysis by HER2 status; the results were similar (data not shown).
Finally, the results for all three density measures were similar
when the analysis was restricted to invasive cancers only (data not
shown).
Table 3. ( Continued )
Tumor subtype by receptor status
Marker-positive Marker-negative
Tumour Marker Percent density category No. cases/controls OR (95% CI) No. cases/controls OR (95% CI) P-valueb
AR Total 301/2052 105/2052
o10% 49/461 1.00 (referent) 18/461 1.00 (referent) 0.35
10–24% 82/727 1.10 (0.75–1.61) 26/727 0.99 (0.53–1.86)
25–49% 119/651 1.83 (1.24–2.70) 36/651 1.70 (0.90–3.21)
X50 51/213 2.53 (1.56–4.10) 25/213 4.27 (2.06–8.86)
Ptrend o0.0001 o0.0001
EGFR Total 48/2052 249/2052
o10% 8/461 1.00 (referent) 35/461 1.00 (referent) 0.36
10–24% 16/727 1.37 (0.57–3.32) 73/727 1.36 (0.88–2.10)
25–49% 19/651 1.97 (0.79–4.93) 105/651 2.48 (1.60–3.86)
X50 5/213 1.89 (0.55–6.55) 36/213 2.97 (1.70–5.19)
Ptrend 0.18 o0.0001
VEGF Total 145/2052 37/2052
o10% 26/461 1.00 (referent) 4/461 1.00 (referent) 0.35
10–24% 40/727 1.08 (0.64–1.84) 8/727 1.10 (0.32–3.85)
25–49% 51/651 1.53 (0.89–2.61) 18/651 2.52 (0.76–8.33)
X50 28/213 2.68 (1.41–5.12) 7/213 3.01 (0.74–12.29)
Ptrend 0.0009 0.04
Abbreviations: AR¼ androgen receptor; CI¼ confidence interval; CK5/6¼ cytokeratins 5/6; EGFR¼epidermal growth factor receptor; ER¼oestrogen receptor; HER2¼ human epidermal
growth factor receptor 2; Ki67¼proliferation marker; OR¼odds ratio; PR¼progesterone receptor; SE¼ standard error; VEGF¼ vascular endothelial growth factor.
aPolychotomous multivariable logistic regression model adjusted for age (continuous), body mass index (continuous), age at menarche (o12, 12, 13, or413 years), parity and age at first birth
(nulliparous, 1–4 children with age at first birtho25 years, 1–4 children with age at first birth of 25–29 years, 1–4 children with age at first birth ofX30 years,X5 children with age at first birth of
o25 years, orX5 children with age at first birth ofX25 years), age at menopause (o46, 46–o50, 50–o55,X55, unknown), postmenopausal hormone use (never, ever, unknown), family history
(yes or no), confirmed history of benign breast disease (yes or no), alcohol consumption (0, o5, 5 to o15, or X15g per day), and NHS cohort (NHS II vs NHS).
bP-values for the test of heterogeneity of odds ratios were calculated using a two-sided likelihood ratio test.
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DISCUSSION
In this nested case-control study, we investigated the associations
of percent breast density, absolute dense area, and non-dense area
with breast cancer risk according to the status of selected tissue
markers among 1010 postmenopausal breast cancer cases and 2077
matched controls. The strength of the associations of absolute
dense area and non-dense area with breast cancer risk varied by
ER, CK5/6, AR, and EGFR status. Stronger positive associations
were noted for absolute dense area and CK5/6 and EGFR
tumours. Stronger inverse associations of non-dense area with
breast cancer risk were observed in ER , ARþ , CK5/6þ , and
EGFRþ tumours. We did not find differences in the associations
of density measures with breast cancer risk according to the status
of other markers.
We have previously reported a stronger association of percent
breast density with ER tumours (Yaghjyan et al, 2011, Bertrand
et al, 2013). Similar to our previous results, we observed suggestive
stronger associations in ER than ERþ tumours with percent
density, though this difference did not reach statistical significance.
Findings on the association of breast density with receptor status of
the tumour from previous studies are inconsistent (Yaghjyan et al,
2011, Antoni et al, 2013, Pollan et al, 2013), although one of the
largest studies to date showed a stronger association of percent
density with ER than ERþ breast cancer among younger
women (Bertrand et al, 2013). Our findings suggest that regulatory
factors other than oestrogen may play an important role in the
origins of ER tumours in denser breasts. Finally, it appears that
this association is being driven in large part by non-dense area
rather than absolute dense area.
We found a stronger inverse association between non-dense
breast area and ER tumours compared with ERþ tumours.
Similarly, a recent pooled analysis of 4095 breast cancers and 8558
controls have reported a stronger inverse association of non-dense
area with ER tumours among younger women (age o55 years)
(Bertrand et al, 2015). As recently discussed, non-dense area that
represents breast adipose tissue may influence breast cancer risk
through both direct and indirect mechanisms (Pettersson and
Tamimi, 2012). The stronger inverse association observed for
ER tumours, suggests that breast adipose tissue (as measured by
non-dense area) could be reducing risk through non-oestrogen
mediated pathways.
We describe, for the first time, a stronger positive association of
absolute dense area with CK5/6 , EGFR , and AR tumours,
and stronger inverse associations of non-dense area with CK5/6þ ,
EGFRþ , and ARþ tumours. The association patterns observed in
our study could only in part be explained by the moderate positive
correlations of ER with AR and inverse correlations with EGFR. It
has been suggested that the amount of stromal matrix and
glandular elements and their interaction with each other are
implicated in breast carcinogenesis (Shepherd and Kerlikowske,
2012). On the other hand, expression of certain tissue markers
could be reflective of the tissue composition. Thus, in the studies
investigating associations of breast density with molecular subtypes
of breast cancer absolute dense and non-dense areas appear to be
more relevant density measures that would allow detection of
differences in subtype-specific associations. As CK5/6 and EGFR
are predominantly expressed in stromal and epithelial cells, the
protective effect of non-dense tissue on CK5/6þ and EGFRþ
subtypes could be the result of interaction between fibroglandular
and adipose elements in the breast tissue. The underlying biological
mechanisms by which absolute dense and non-dense areas could
differentially affect the risk of specific molecular subtypes of breast
cancer yet need to be elucidated.
To our knowledge, this is the first large study to investigate the
association of three quantitative measures of breast density with
several tissue markers. The analysis used data from the NHS, an
established cohort with more than 30 years of follow-up, disease
status ascertainment, and comprehensive information on breast
cancer risk factors, tumour characteristics, and breast density. The
current analysis was restricted to women who were postmenopau-
sal at the time of both mammogram and diagnosis, which
constitutes the majority of the population assembled for the nested
case-control study (62%). Our findings are thus limited to
postmenopausal breast cancer subtypes and do not necessarily
apply to premenopausal breast cancer. In addition, we did not
investigate the associations between breast density and breast
cancer risk by combined ER/PR/HER2 status or by combined CK5/
6/EGFR status because the small numbers of tumours in the
subsets did not provide sufficient statistical power to draw
meaningful conclusions. Finally, as the marker data for Ki67,
AR, CK5/6, EGFR, and VEGF were available on a small subset of
cases, these exploratory findings should be interpreted with
caution.
Breast cancer is a heterogeneous disease. Previous studies
suggested aetiological heterogeneity of ERþ and ER tumours
(Colditz et al, 2004, Rusiecki et al, 2005, Yang et al, 2007, Kwan
et al, 2009). Some recent studies suggest that clinical outcomes and
patient survival can differ by tumour CK5/6, EGFR, VEGF, and AR
status (Collins et al, 2011, Dawood et al, 2011, Hu et al, 2011, Liu
et al, 2011). While expression of CK5/6, EGFR, and VEGF involved
in cellular proliferation, differentiation, and angiogenesis has been
linked to a more aggressive tumour phenotype and poorer survival,
ARþ tumours seem to have more favourable outcomes (Collins
et al, 2011, Hu et al, 2011), perhaps due to the inhibition of growth
of breast cancer cells through the androgen signalling pathway
(Birrell et al, 2007). Identifying risk factors specific to certain
molecular subtypes of breast tumours would help researchers to
understand the aetiology of those breast cancer subtypes and
develop subtype-specific risk prediction models.
In conclusion, we investigated the association of breast
density with tissue marker-defined breast cancer subtypes in
postmenopausal women. Our results suggest that breast
density influences the risk of breast cancer subtypes by potentially
different mechanisms. Further studies are warranted to explain
underlying biological processes and elucidate the possible
pathways from high breast density to the specific subtypes of
breast carcinomas.
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